Day: May 3, 2021

New Integration Provides Box Users Worldwide Access to Automated Audio Enhancement Tools Powered by Industry-Defining Dolby TechnologyBox with Dolby.ioBox, the leading Content Cloud, and Dolby, a leader in immersive entertainment experiences, announced a new integration that makes production-quality audio as simple as uploading a file to Box.REDWOOD CITY, Calif. and SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) — Box, Inc. (NYSE:BOX), the leading Content Cloud, and Dolby Laboratories, Inc. (NYSE:DLB), a leader in immersive entertainment experiences, announced a new integration that makes production-quality audio as simple as uploading a file to Box. With Dolby.io, companies using Box can offer their users seamless and cost-effective audio enhancement tools that leverage Dolby’s decades of expertise enabling best-in-class...

Firm Orders Now Total Approximately $3.6 Million EDGEWOOD, N.Y., May 03, 2021 (GLOBE NEWSWIRE) — CPI Aerostructures, Inc. (“CPI Aero®”) (NYSE American: CVU) today announced that it was awarded a follow-on order for nearly $1 million from Spirit AeroSystems (NYSE: SPR) to manufacture cabin rack assemblies for new production CH-53K King Stallion Helicopters, built by Sikorsky Aircraft. Deliveries are scheduled for 2022. Including this new order, total orders from Spirit AeroSystems for CH-53K assemblies now total approximately $3.6 million. CPI Aero president and CEO Douglas McCrosson stated, “CPI is proud to be the single source supplier of these assemblies for the CH-53K King Stallion. The USMC is looking to complete Initial Operational Test & Evaluation (IOT&E) and declare Initial Operational Capability (IOC) for the...

TEMPE, Ariz., May 03, 2021 (GLOBE NEWSWIRE) — Align Technology, Inc. (“Align”) (Nasdaq: ALGN) today announced that it has entered into an accelerated stock repurchase agreement (“ASR”) with Goldman Sachs & Co LLC, to repurchase $100 million of Align’s common stock to complete its $600 million stock repurchase program announced on May 23, 2018.  Under the terms of the ASR, Align will receive an initial delivery of approximately 134,300 shares. The final number of shares to be repurchased will be based on Align’s volume-weighted average stock price during the term of the ASR, less an agreed upon discount. The ASR transaction is expected to be completed by August 2021 and will be funded with Align’s cash on hand. As of March 31, 2021, Align had approximately 79.1 million shares outstanding and $1.1 billion...

DENVER, May 03, 2021 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (“IONM”), is pleased to announce that it has completed the previously announced acquisition (the “Acquisition”) of all of the assets (the “Acquired Assets”) of Sentry Neuromonitoring, LLC (“Sentry”), one of the largest IONM service providers in Texas. As a result of the closing of the Acquisition, the Company raised its guidance for full-year 2021 total procedures from 14,000 to 17,000. This number represents an anticipated increase in cases of more than 70% compared with 2020 and an increase of 165% since 2019. Assure acquired Sentry, a Joint Commission certified IONM company primarily serving the Greater Houston region. Sentry’s operational footprint also extends...

SOUTH SAN FRANCISCO, Calif., May 03, 2021 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2021, and provided business highlights. “Our programs have reached a number of exciting milestones so far this year across our broad portfolio of targeted therapeutics for neurodegenerative diseases,” said Ryan Watts, Ph.D., Denali’s Chief Executive Officer. “We remain focused on advancing our lead clinical programs including DNL310 for Hunter syndrome, DNL151 (BIIB122) in collaboration with Biogen for Parkinson’s disease, and DNL343 for amyotrophic lateral sclerosis (ALS). In addition, based on...

AUSTIN, Texas, May 03, 2021 (GLOBE NEWSWIRE) — Ideal Power Inc. (Nasdaq: IPWR), pioneering the development and commercialization of highly efficient and broadly patented B-TRAN™ bi-directional power switches, today announced that management will hold a conference call on Thursday, May 13, 2021 at 4:30 p.m. Eastern Time to discuss its results for the first quarter ended March 31, 2021. A press release detailing these results will be issued prior to the call. Ideal Power President and CEO Dan Brdar and CFO Tim Burns will host the conference call, followed by a question-and-answer period. To access the call, please use the following information:Date: Thursday, May 13, 2021 Time: 4:30 p.m. EDT, 1:30 p.m. PDTToll-free dial-in number: 1-866-248-8441International dial-in number: 1-323-289-6581Conference ID:  3477153Please...

IRVINE, Calif., May 03, 2021 (GLOBE NEWSWIRE) — Viant Technology Inc. (NASDAQ: DSP), a leading people-based advertising software company, today announced that members of its management team are scheduled to present at upcoming investor conferences. Details for each event are as follows: 16th Annual Needham Virtual Technology & Media ConferenceTuesday, May 18, 2021 at 2:15 pm ET Bank of America Global Technology ConferenceWednesday, June 9, 2021 at 2:30 pm ET The presentations will be webcast live on the investor relations section of Viant’s website at investors.viantinc.com. Replays of the presentations will be available on the website following the completion of each event. About ViantViant® is a leading people-based advertising software company that enables marketers and their agencies to centralize the planning, buying...

– Topline data on track for readout before the end of Q2 2021 – – Currently no FDA-approved therapies for the treatment of molluscum – – Potential for NDA filing no later than Q3 2022 – DURHAM, N.C., May 03, 2021 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the final patient has completed their last Week-12 visit in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum (“molluscum”). Topline efficacy and safety results from the B-SIMPLE4 study are targeted to be reported before the end of the second quarter of 2021. “We are incredibly pleased with the progress we have continued to make as we advance our lead program. We remain focused on executing our remaining steps according to plan and reporting topline efficacy...

JV Announces Demonstration to 100 Schools, 1,000 Classes and 10,000 Learners TORONTO, May 03, 2021 (GLOBE NEWSWIRE) — ARHT Media Inc. (“ARHT” or “the Company”) (TSXV:ART), the global leader in the development, production and distribution of high-quality, low latency hologram and digital content, is pleased to announce that it has been the holographic technology supplier to a joint venture in China between Net Dragon Websoft Holdings and China Unicom. Last week this joint venture announced that it is launching the New Infrastructure “5G+Smart Education” Application Demonstration Project. Based on technologies such as 5G, VR, AR, holographic classrooms and ultra-high-definition video, it aims to provide an exemplar of “5G+Smart Education” applications with the participation of a hundred schools, a thousand...

EWING, N.J., May 03, 2021 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that data highlighting the therapeutic potential of subcutaneous testosterone enanthate in younger hypogonadal populations was presented in a poster presentation at the Pediatric Endocrine Society (PES) 2021 Virtual Annual Meeting on April 30 – May 3, 2021. The poster presentation entitled, “Allometric Scaling of Testosterone Enanthate Pharmacokinetics from Adult Males to Adolescent Hypogonadal Males (30-60 kg) After IM and SC Administration Using Population PK Modeling”, was presented by Maria Vogiatzi, MD*, Professor of Pediatrics and Director, Adrenal and Puberty Center, Division of Endocrinology and Diabetes, Children’s Hospital of Philadelphia, Philadelphia, PA. Pharmacokinetic...